Home/ Products / Full-length Membrane Proteins
DMF1022-50ug
50 ug
$1,800
DMF1022-100ug
100 ug
$2,400
| target | CLDN18.2 |
| gene name | CLDN18 |
| alias | Claudin 18.2 |
| gene id | Uniprot ID: P56856 |
| tags | None |
| conjugate | None |
| host species | Human |
| production host | HEK293 |
| formulation | Lyophilized from sterile PBS, pH 7.4. Normally 5% - 8% trehalose is added as protectants before lyophilization. |
| reconstitution | Reconstitute lyophilized powder with water to a concentration of no less than 100 ug/ml, solubilize with occasional gentle mixing. Do not use solvents with pH lower than 6.5 in subsequent experiments. |
| shipping | Shipped at ambient conditions. |
| storage | Lyophilized form is stable for 1 week at room temperature. Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, store at 4°C for 2-7 days or at below -20°C for up to 3 months. |
ELISA plates were pre-coated with 0.5 ug per well purified human CLDN18.2 VLP. Serial diluted Anti-CLDN18.2 monoclonal antibody (Zolbetuximab biosililar; IMAB362) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for IMAB362 binding with CLDN18.2 VLP is 15.37 ng/ml.
FACS analysis of CLDN18.2 VLP. A. Negative Control 1: CLDN18.2 VLP were stained only with Goat anti-human IgG Fc-PE secondary antibody. B. Negative Control 2: Control VLP were stained with anti-CLDN18.2 antibody (Zolbetuximab biosimilar; IMAB362) at 1 ug/ml, followed by Goat anti-human IgG Fc-PE secondary antibody. C. Negative Control 3: CLDN18.2 VLP were stained with anti-BCMA antibody?an irrelevant antibody?at 1 ug/ml, followed by Goat anti-human IgG Fc-PE secondary antibody. D. CLDN18.2 VLP were stained with anti-CLDN18.2 antibody?Zolbetuximab biosimilar; IMAB362?at 1 ug/ml, followed by Goat anti-human IgG Fc-PE secondary antibody.
DMF1022-50ug
50 ug
$1,800
DMF1022-100ug
100 ug
$2,400